BR112018075086A2 - derivados de pirazolilaminobenzimidazol como inibidores de jak - Google Patents
derivados de pirazolilaminobenzimidazol como inibidores de jakInfo
- Publication number
- BR112018075086A2 BR112018075086A2 BR112018075086-7A BR112018075086A BR112018075086A2 BR 112018075086 A2 BR112018075086 A2 BR 112018075086A2 BR 112018075086 A BR112018075086 A BR 112018075086A BR 112018075086 A2 BR112018075086 A2 BR 112018075086A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrazolylaminobenzimidazole
- derivatives
- jak inhibitors
- compounds
- jak
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- DHHDAEXWDQTBIJ-UHFFFAOYSA-N n-(1h-pyrazol-5-yl)-1h-benzimidazol-2-amine Chemical class N=1C2=CC=CC=C2NC=1NC1=CC=NN1 DHHDAEXWDQTBIJ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
a presente invenção fornece compostos da fórmula (i?) abaixo: onde r, e r1-r3 são como descritos aqui, métodos de tratamento de pacientes para determinados tipos de doenças autoimunes e câncer, e processos para a preparação dos compostos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662362208P | 2016-07-14 | 2016-07-14 | |
| US62/362,208 | 2016-07-14 | ||
| PCT/US2017/041388 WO2018013486A1 (en) | 2016-07-14 | 2017-07-10 | Pyrazolylaminobenzimidazole derivatives as jak inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018075086A2 true BR112018075086A2 (pt) | 2019-03-12 |
| BR112018075086B1 BR112018075086B1 (pt) | 2024-02-27 |
Family
ID=59366549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018075086-7A BR112018075086B1 (pt) | 2016-07-14 | 2017-07-10 | Derivados de pirazolilaminobenzimidazol, seu uso, e composição farmacêutica |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10323019B2 (pt) |
| EP (1) | EP3484875B1 (pt) |
| JP (1) | JP6712331B2 (pt) |
| KR (1) | KR102225840B1 (pt) |
| CN (1) | CN109476643B (pt) |
| AU (1) | AU2017296026B2 (pt) |
| BR (1) | BR112018075086B1 (pt) |
| CA (1) | CA3030697C (pt) |
| CY (1) | CY1124308T1 (pt) |
| DK (1) | DK3484875T3 (pt) |
| EA (1) | EA038129B1 (pt) |
| ES (1) | ES2877198T3 (pt) |
| HR (1) | HRP20210965T1 (pt) |
| HU (1) | HUE054912T2 (pt) |
| LT (1) | LT3484875T (pt) |
| MX (1) | MX2019000542A (pt) |
| NZ (1) | NZ748942A (pt) |
| PL (1) | PL3484875T3 (pt) |
| PT (1) | PT3484875T (pt) |
| RS (1) | RS61991B1 (pt) |
| SI (1) | SI3484875T1 (pt) |
| WO (1) | WO2018013486A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230141115A (ko) | 2022-03-31 | 2023-10-10 | 한림대학교 산학협력단 | 신규한 2-아릴-1H-벤조[d]이미다졸 유도체, 이의 제조 방법 및 이의 항암제로서의 용도 |
| KR102582097B1 (ko) | 2022-12-28 | 2023-09-25 | (주)메디언스 | 야누스키나아제 표적 억제제 및 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010524911A (ja) * | 2007-04-18 | 2010-07-22 | アストラゼネカ アクチボラグ | ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用 |
| US8445676B2 (en) * | 2008-10-08 | 2013-05-21 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2010068806A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| CN102712640A (zh) * | 2010-01-12 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 三环杂环化合物、其组合物和应用方法 |
| AR083933A1 (es) * | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| WO2013040863A1 (en) * | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors |
| GB201401086D0 (en) | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2016065138A1 (en) * | 2014-10-22 | 2016-04-28 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| AR105400A1 (es) * | 2015-08-04 | 2017-09-27 | Lilly Co Eli | Inhibidores de jak1 |
-
2017
- 2017-07-10 NZ NZ748942A patent/NZ748942A/en unknown
- 2017-07-10 WO PCT/US2017/041388 patent/WO2018013486A1/en active Application Filing
- 2017-07-10 BR BR112018075086-7A patent/BR112018075086B1/pt active IP Right Grant
- 2017-07-10 HU HUE17740885A patent/HUE054912T2/hu unknown
- 2017-07-10 JP JP2018567741A patent/JP6712331B2/ja active Active
- 2017-07-10 CA CA3030697A patent/CA3030697C/en active Active
- 2017-07-10 SI SI201730827T patent/SI3484875T1/sl unknown
- 2017-07-10 DK DK17740885.3T patent/DK3484875T3/da active
- 2017-07-10 PL PL17740885T patent/PL3484875T3/pl unknown
- 2017-07-10 PT PT177408853T patent/PT3484875T/pt unknown
- 2017-07-10 ES ES17740885T patent/ES2877198T3/es active Active
- 2017-07-10 KR KR1020197000782A patent/KR102225840B1/ko active IP Right Grant
- 2017-07-10 AU AU2017296026A patent/AU2017296026B2/en active Active
- 2017-07-10 RS RS20210756A patent/RS61991B1/sr unknown
- 2017-07-10 EA EA201892698A patent/EA038129B1/ru not_active IP Right Cessation
- 2017-07-10 EP EP17740885.3A patent/EP3484875B1/en active Active
- 2017-07-10 CN CN201780043606.5A patent/CN109476643B/zh active Active
- 2017-07-10 MX MX2019000542A patent/MX2019000542A/es unknown
- 2017-07-10 LT LTEP17740885.3T patent/LT3484875T/lt unknown
- 2017-07-10 US US15/775,990 patent/US10323019B2/en active Active
-
2019
- 2019-02-12 US US16/273,706 patent/US10344018B2/en active Active
-
2021
- 2021-06-17 HR HRP20210965TT patent/HRP20210965T1/hr unknown
- 2021-07-02 CY CY20211100588T patent/CY1124308T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3484875T1 (sl) | 2021-08-31 |
| MX2019000542A (es) | 2019-07-04 |
| EP3484875B1 (en) | 2021-04-07 |
| CN109476643B (zh) | 2021-06-08 |
| JP6712331B2 (ja) | 2020-06-17 |
| WO2018013486A1 (en) | 2018-01-18 |
| HUE054912T2 (hu) | 2021-10-28 |
| EP3484875A1 (en) | 2019-05-22 |
| PT3484875T (pt) | 2021-07-05 |
| CA3030697A1 (en) | 2018-01-18 |
| KR102225840B1 (ko) | 2021-03-11 |
| US10344018B2 (en) | 2019-07-09 |
| DK3484875T3 (da) | 2021-06-28 |
| ES2877198T3 (es) | 2021-11-16 |
| RS61991B1 (sr) | 2021-07-30 |
| JP2019525908A (ja) | 2019-09-12 |
| EA201892698A1 (ru) | 2019-06-28 |
| NZ748942A (en) | 2020-08-28 |
| HRP20210965T1 (hr) | 2021-09-17 |
| KR20190015561A (ko) | 2019-02-13 |
| AU2017296026A1 (en) | 2018-12-20 |
| CN109476643A (zh) | 2019-03-15 |
| AU2017296026B2 (en) | 2019-11-21 |
| CY1124308T1 (el) | 2022-07-22 |
| US20190177300A1 (en) | 2019-06-13 |
| US10323019B2 (en) | 2019-06-18 |
| CA3030697C (en) | 2021-02-23 |
| LT3484875T (lt) | 2021-07-26 |
| PL3484875T3 (pl) | 2021-11-02 |
| US20180325873A1 (en) | 2018-11-15 |
| BR112018075086B1 (pt) | 2024-02-27 |
| EA038129B1 (ru) | 2021-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202191730A1 (ru) | Ингибиторы kif18a | |
| BR112019002275A2 (pt) | inibidores aminopirimidina de ssaos | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| BR112017019287A2 (pt) | composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit | |
| CO2017011484A2 (es) | Inhibidores de bromodominio | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| MY197440A (en) | Heteroamatic compounds as btk inhibitors | |
| BR112018068412A2 (pt) | composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral | |
| PH12019502693A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| PH12017501130A1 (en) | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | |
| PH12021551280A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| MX2021006489A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| EA201992302A1 (ru) | Соединения, используемые в качестве ингибиторов alcat1 | |
| CY1124308T1 (el) | Παραγωγα πυραζολυλαμινοβενζιμιδαζολης ως αναστολεις της jak | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| MX2021006490A (es) | Compuestos heteroaromaticos como inhibidores de vanina. | |
| EA201650085A1 (ru) | Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида | |
| EA201791745A1 (ru) | Производные тетрагидропиранилбензамида | |
| BR112017013194A2 (pt) | síntese total de trioxacarcina dc-45-a2 e preparação de análogos de trioxacarcina | |
| BR112019001824A2 (pt) | compostos de tiazol-piridina substituídos como inibidores de malt1 | |
| BR112018012341A2 (pt) | compostos úteis como inibidores da quinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2017, OBSERVADAS AS CONDICOES LEGAIS |